Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population

Documenti analoghi

• Successful management of euglycaemic diabetic ketoacidosis in a bexagliflozin‐treated cat
  di: Ingrid Madeleine Preteseille, et al.
  Pubblicazione: (2025)
• Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure
  di: Yuliya Lytvyn, et al.
  Pubblicazione: (2025)
• Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors
  di: Anat Tsur, et al.
  Pubblicazione: (2025)
• Risk of recurrent diabetic ketoacidosis following initiation of sodium‐glucose co‐transporter 2 inhibitors in patients with an insulin‐deficient diabetes and prior diabetic ketoacidosis: An observational cohort study
  di: Anat Tsur, et al.
  Pubblicazione: (2026)
• Choosing oral antihyperglycaemic drugs in people living with Type 2 diabetes and severe chronic kidney disease
  di: Mikael Rydén
  Pubblicazione: (2025)